
CLAIMS


1. Use of a Bedaquiline derivative with a TPP moiety in the manufacture of a medicament for treating or preventing at least one of tumor recurrence and metastasis in a subject.

2. The use of claim 1, wherein the Bedaquiline derivative with a TPP moiety is:




, wherein m and n are independently an integer from 0 to 16; A is O, N, or S; and X is a halogen or a pharmaceutically acceptable anion.

3. The use of claim 1, wherein the Bedaquiline derivative with a TPP moiety is:




, wherein m and n are independently an integer from 0 to 16; A and B are independently O, N, S, or absent; and X is a halogen or a pharmaceutically acceptable anion.

4. The use of claim 1, wherein the Bedaquiline derivative with a TPP moiety is:




.

5. The use of claim 1, wherein the Bedaquiline derivative with a TPP moiety is:




.

6. A compound of the structure:




, wherein m and n are independently an integer from 0 to 16; A is O, N, or S; and X is a halogen or a pharmaceutically acceptable anion.

7. The compound of claim 5, wherein the compound is:




.

8. The compound of claim 5, wherein the compound is:



9. A compound of the structure:



, wherein m and n are independently an integer from 0 to 16; A and B are independently O, N, S, or absent; and X is a halogen or a pharmaceutically acceptable anion.

10. Use of a composition containing an active compound selected from Bedaquiline and a Bedaquiline derivative with a TPP moiety in the manufacture of a medicament for preventing and/or reducing the likelihood of tumor metastasis and tumor recurrence in a patient, wherein the preventing and/or reducing the the likelihood of tumor metastasis and tumor recurrence comprises:

determining, or having determined, the level of biomarkers in a biological sample obtained from the patient of a ATP-related metastasis gene-signature consisting of ABCA2, ATP5F1C, COX20, NDUFA2 and UQCRB;

comparing the determined level to a threshold level for the biomarkers; and

administering the medicament if the determined level exceeds the threshold level.

11. The use of claim 10, wherein the Bedaquiline derivative with a TPP moiety is a compound of any one of claims 6-9.

12. Use of a Bedaquiline derivative with a TPP moiety in the manufacture of a medicament for treating an individual with cancer.

13. The use of claim 12, wherein the Bedaquiline derivative with a TPP moiety is a compound of any one of claims 6-9.

14. The use of claim 12, wherein the cancer is breast cancer.